ASN’s annual Board Review Course & Update (BRCU) is an important educational activity for fellows preparing for initial board certification, reaching approximately 400 in-person/live learners and 400 online learners annually in a "normal" year. Due to the uncertainties and challenges relative to COVID-19, the BRCU 2020 in-person event was cancelled, and BRCU 2021 was offered for the first time as a fully virtual event.
ASN’s annual Board Review Course & Update (BRCU) is an important educational activity for fellows preparing for initial board certification, nephrologists preparing for recertification, and other kidney professionals looking for a refresher on core nephrology topics. In a “normal” year, BRCU reaches approximately 400 in-person/live learners and 400 online learners annually.
Due to the uncertainties and challenges relative to COVID-19, the BRCU 2020 in-person event was cancelled, and BRCU 2021 was offered for the first time as a fully virtual event. The BRCU Education Co-Directors, Laura J. Maursetter, DO, FASN, and Roger A. Rodby, MD, FASN, along with 30+ faculty and ASN education and meetings staff had to reimagine the course from its traditional in-person format to a virtual experience within three months—a major undertaking.
BRCU Virtual 2021 was launched in a new online platform on Monday, July 12, with on-demand presentations and continued with live-streamed and simulive sessions on Saturday, July 17, through Thursday, July 22.
Highlights include:
Back by popular demand, BRCU “pearls” are emailed weekly through early October for continued learning and board preparation. Additionally, all participants have access to the course content for three years. For those who missed the virtual event, BRCU Online 2021 is now available in the ASN Store .
The BRCU 2021 experience will help enhance next year’s course in whichever format offered. Visit the ASN website in January for updates.
ASN thanks the following companies for educational grants in support of BRCU Virtual 2021: Akebia Therapeutics, Inc.; AstraZeneca; Vifor Pharma, Inc.